Immunohistochemical and histomorphological analysis of rat mammary tumors after simvastatin treatment

Neoplasma

Volumn 59, Issue 5, 2012, Pages 516-523

  Kubatka, P ^a,b   Kajo, K ^c   Zihlavnikova, K ^a   Adamicova, K ^a,d   Vybohova, D ^a   Pec, M ^a,b   Nosal, V ^e   Stollarova, N ^b   Bojkova, B ^f   Kassayova, M ^f   Orendas, P ^f  

^a Physics and Informatics   (Slovakia)

^b CATHOLIC UNIVERSITY IN RU OMBEROK   (Slovakia)

^c SLOVAK MEDICAL UNIVERSITY   (Slovakia)

^d Diagnostic Centre Ltd   (Slovakia)

^e Martinska Fakultna Nemocnica   (Slovakia)

^f P J AFÁRIK UNIVERSITY   (Slovakia)

Author keywords

Bax; Bcl 2; Ki67; Mammary tumors; Rat; Simvastatin

Indexed keywords

KI 67 ANTIGEN; PROTEIN BAX; PROTEIN BCL 2; SIMVASTATIN; BAX PROTEIN, RAT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; AUTOPSY; BREAST TUMOR; CANCER GRADING; CARCINOGENESIS; CELL PROLIFERATION; CLINICAL EVALUATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; MORBIDITY; MORPHOMETRICS; NONHUMAN; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RAT; ANIMAL; CELL CYCLE; DRUG EFFECT; ENZYME IMMUNOASSAY; EXPERIMENTAL NEOPLASM; METABOLISM; PATHOLOGY; SPRAGUE DAWLEY RAT;

ANIMALS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CELL CYCLE; CELL PROLIFERATION; FEMALE; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMUNOENZYME TECHNIQUES; MAMMARY NEOPLASMS, ANIMAL; PROTO-ONCOGENE PROTEINS C-BCL-2; RATS; RATS, SPRAGUE-DAWLEY; SIMVASTATIN;

EID: 84866767682     PISSN: 00282685     EISSN: 13384317     Source Type: Journal    
DOI: 10.4149/neo_2012_066     Document Type: Article

References (30)

1. HINDLER K, CLEELAND CHS, RIVERA E, COLLARD CHD The role of statins in cancer therapy. Oncologist 2006; 11: 306-315. http://dx.doi.org/10.1634/theoncologist.11-3-306
2. RAO S, LOWE M, HERLICZEK TW, HERLICZEK T, LOWE M, KEYOMARSI K Lovastatin mediated G1 arrest in normal and tumor breast cells is through inhibition of DK2 activity and redistribution of p21 and p27, independent of p53. Oncogene 1998; 17: 2393-2302. http://dx.doi.org/10.1038/sj.onc.1202322
3. DENOYELLE C, VASSE M, KORNER M, MISHAL Z, GANNE F et al. Cerivastatin, an inhibitor of HMGCoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: an in vitro study. Carcinogenesis 2001; 22: 1139-1148. http://dx.doi.org/10.1093/carcin/22.8.1139
4. JIANG Z, ZHENG X, LYTLE RA, HIGASHIKUBO R, RICH KM Lovastatin-induced up-regulation of the BH3-only protein, Bim, and cell death in glioblastoma cells. J Neurochem 2004; 89: 168-178. http://dx.doi.org/10.1111/j.1471-4159.2004.02319.x
5. CAFFORIO P, DAMMACCO F, GERNONE A, SILVESTRIS F Statins activate the mitochondrial pathway of apoptosis in human lymphoblasts and myeloma cells. Carcinogenesis 2005; 26: 883-891. http://dx.doi.org/10.1093/carcin/bgi036
6. AGARWAL B, BHENDWAL S, HALMOS B, MOSS SF, RAMEY WG et al. Lovastatin Augments Apoptosis Induced by Chemotherapeutic Agents in Colon Cancer Cells. Clin Cancer Res 1999; 5: 2223-2229.
7. OGUNWOBI OO, BEALES IL Statins inhibit proliferation and induce apoptosis in Barrett's esophageal adenocarcinoma cells. Am J Gastroenterol 2008; 103: 838-841.
8. ZHANG W, WU JA, ZHOU L, XIE HY, ZHENG SS Fluvastatin, a lipophilic statin, induces apoptosis in human hepatocellular carcinoma cells through mitochondria-operated pathway. Indian J Exp Biol 2010; 48: 1167-1174.
9. KUBATKA P, ZIHLAVNIKOVA K, SOLAR P, KAJO K, VALENTOVA V et al. Antitumor effects of atorvastatin in the chemoprevention of rat mammary carcinogenesis. Biologia 2011; 66: 727-734. http://dx.doi.org/10.2478/s11756-011-0077-3
10. SCHOLZEN T, GERDES J The Ki-67 protein: from the known and the unknown. J Cell Physiol 2000; 182: 311-322. http://dx.doi.org/10.1002/(SICI)1097-4652(200003)182:3311::AID-JCP13.0.CO;2-9
11. RUSSO J, RUSSO IH Atlas and histologic classification of tumors of the rat mammary gland. J. Mammary Gland Biol. Neoplasia 2000; 5: 187-200. http://dx.doi.org/10.1023/A:1026443305758
12. KUBATKA P, ZIHLAVNIKOVA K, KAJO K, PEC M, STOLLAROVA N et al. Antineoplastic effects of simvastatin in experimental breast cancer. Klin Onkol 2011; 24: 41-45
13. KUBATKA P, ZIHLAVNIKOVA K, KAJO K, STOLLAROVA N, PEC M et al. Rosuvastatin in the chemoprevention of Nmethyl-N-nitrosourea-induced mammary carcinogenesis in female rats. Acta Vet (Beograd) 2011; 61: 445-460. http://dx.doi.org/10.2298/AVB1106445K
14. NARISAWA T, FUKAURA Y, TERADA K, UMEZAWA A, TANIDA N et al. Prevention of 1,2-dimethylhydrazineinduced colon tumorigenesis by HMG-CoA reductase inhibitors, pravastatin and simvastatin, in ICR mice. Carcinogenesis 1994; 15: 2045-2048. http://dx.doi.org/10.1093/carcin/15.9.2045
15. TATSUTA M, IISHI H, BABA M, ISEKI K, YANO H et al. Suppression by pravastatin, an inhibitor of p21ras isoprenylation, of hepatocarcinogenesis induced by N-nitrosomorpholine in Sprague-Dawley rats. Br J Cancer 1998; 77: 581-587. http://dx.doi.org/10.1038/bjc.1998.94
16. NARISAWA T, MOROTOMI M, FUKAURA Y, HASEBE M, ITO M et al. Chemoprevention by pravastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, of N-methyl-N-nitrosourea-induced colon carcinogenesis in F344 rats. Jpn J Cancer Res 1996; 87: 798-804. http://dx.doi.org/10.1111/j.1349-7006.1996.tb02103.x
17. PARK C, LEE I, KANG WK Lovastatin-induced E2F-1 modulation and its effect on prostate cancer cell death. Carcinogenesis 2001; 22: 1727-1731. http://dx.doi.org/10.1093/carcin/22.10.1727
18. VAN DE DONK NW, KAMPHUIS MM, LOKHORST HM, BLOEM AC The cholesterol lowering drug lovastatin induces cell death in myeloma plasma cells. Leukaemia (Baltimore) 2002; 16: 1362-1371.
19. LI D, LI Y, HERNANDEZ JA, PATENIA R, KIM TK et al. Lovastatin inhibits T-cell proliferation while preserving the cytolytic function of EBV, CMV, and MART-1-specific CTLs. J Immunother 2010; 33: 975-982. http://dx.doi.org/10.1097/CJI.0b013e3181fb0486
20. BESSLER H, SALMAN H, BERGMAN M, DJALDETTI M On the factors modulating the effect of statins on malignant cell proliferation. Cancer Invest 2007; 25: 279-284. http://dx.doi.org/10.1080/07357900701208535
21. DE AZAMBUJA E, CARDOSO F, DE CASTRO JR G, COLOZZA M, MANO MS, et al. Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12155 patients. Br J Cancer 2007; 96: 1504-1513. http://dx.doi.org/10.1038/sj.bjc.6603756
22. YE F, ZHANG GH, GUAN BX, XU XC. Suppression of esophageal cancer cell growth usin curcumin, (-)-epigallocatechin-3-gallate and lovastatin. World J Gastroenterol 2012; 18: 126-135. http://dx.doi.org/10.3748/wjg.v18.i2.126
23. GUIJARRO C, BLANCO-COLIO LM, ORTEGO M, ALONSO C, ORTIZ A et al. 3-Hydroxy-3-methylglutaryl coenzyme A reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture. Circ Res 1998; 83: 490-500.
24. DEMYANETS S, KAUN C, PFAFFENBERGER S, HOHENSINNER PJ, REGA G et al. Hydroxymethylglutaryl-coenzyme A reductase inhibitors induce apoptosis in human cardiac myocytes in vitro. Biochem Pharmacol 2006; 71: 1324-1330. http://dx.doi.org/10.1016/j.bcp.2006.01.016
25. KUBOTA T, FUJISAKI K, ITOH Y, YANO T, SENDO T, OISHI R Apoptotic injury in cultured human hepatocytes induced by HMG-CoA reductase inhibitors. Biochem Pharmacol 2004; 67: 2175-2186. http://dx.doi.org/10.1016/j.bcp.2004.02.037
26. KOYUTURK M, ERSOZ M, ALTIOK N Simvastatin induces proliferation inhibition and apoptosis in C6 glioma cells via c-jun N-terminal kinase. Neurosci Lett 2004; 370: 212-217. http://dx.doi.org/10.1016/j.neulet.2004.08.020
27. KATSIKI N, TZIOMALOS K, CHATZIZISIS Y, ELISAF M, HATZITOLIOS AI Effect of HMG-CoA reductase inhibitors on vascular cell apoptosis: Beneficial or detrimental? Atherosclerosis 2010; 211: 9-14. http://dx.doi.org/10.1016/j.atherosclerosis.2009.12.028
28. KATO S, SMALLEY S, SADARANGANI A, CHEN-LIN K, OLIVA B et al. Lipophilic but not hydrophilic statins selectively induce cell death in gynaecological cancers expressing high levels of HMGCoA reductase. J Cell Mol Med 2010; 14: 1180-1193.
29. SIRVENT JJ, AGUILAR MC, OLONA M, PELEGRI A, BLAZQUEZ S et al. Prognostic value of apoptosis in breast cancer (pT1-pT2). A TUNEL, p53, bcl-2, bag-1 and Bax immunohistochemical study. Histol Histopathol 2004; 19: 759-770.
30. VARGAS-ROIG LM, CUELLO-CARRION FD, FERNANDEZ-ESCOBAR N, DAGUERRE P, LEUZZI M et al. Prognostic value of Bcl-2 in breast cancer patients treated with neoadjuvant anthracycline based chemotherapy. Mol Oncol 2008; 2: 102-111. http://dx.doi.org/10.1016/j.molonc.2008.01.004